Skip to content

Praesidia Biotherapeutics

Maximizing the therapeutic potential of drugs

PRAESIDIA IS DEVELOPING DRUGS WITH INCREASED THERAPEUTIC WINDOW FOR THE BEST POSSIBLE STANDARD OF CARE OUTCOME THROUGH PROPRIETARY ORGAN AND CELL-SPECIFIC DELIVERY, ESPECIALLY ACROSS THE BLOOD-BRAIN BARRIER
technology

The Technology

Developing drugs with increased therapeutic index by:

  • – Reducing systemic toxicity
  • – Release of active drug in targeted organ or tissue

Developing CNS and Oncology drugs

Prioritized pipeline for potential orphan disease indications

De-risked science with potential to displace Standard of Care

Praesidia’s patented first in class Tunable Linker Technology called Linker Enzyme Substrate System or LESS(TM) is designed to increase the therapeutic window of a drug by delivering drug payloads with greater tissue or cell specificity and reduced systemic toxicity. Praesidia has demonstrated this capability with in vivo animal models and are preparing clinical proof.

about

about us

We have come together with the overarching goal of improving the therapeutic outcome of drugs for patients and with an undeterrable motivation to make a positive impact on the society at large, Praesidia is an amalgamation of patient-focused science, successful organization development pedigree with proven value delivery record to investors.

After having worked in stealth mode from 2019-2021, Praesidia raised Series A funding in August 2021. Within a year of funding, we have established proof of concept of our technology for 2 different indications in 2 different target tissues. Having brought together an eminent advisory panel and program-specific Scientific Advisory Board,  the Company is now poised to progress their lead programs to First in Human Clinical Trials by 2024. Pre-clinical data are being developed in labs across the USA, Canada and India, making us highly capital efficient.

team

Our team

Praesidia is a culmination of the two founders’ over 50 years of combined drug development experience.  This encompasses new target and new drug discovery, recombinant protein molecule and monoclonal antibody design, as well as platform development. The R&D experience extends to complete drug development lifecycle: from cell line to process development to scaling up to large scale GMP Manufacturing for clinical studies and market. Our experience and expertise are exponentially enriched by the scientific co-founders and expanding team of advisors with prominent academic, industrial and clinical pedigrees.